(Length of Discussion: 12 min)

Daniel George, MD talks with Charles Ryan, MD and discusses a number of recent studies Daniel and his colleagues at Duke University School of Medicine have been focused on related to race and abiraterone outcomes in prostate cancer patients and how this new information impacts clinical practice. 


Studies and Presentations Discussed in Discussion:

Overall Survival Between African-American and Caucasian Men with Metastatic Castration-Resistant Prostate Cancer

Abi Race: A Prospective, Multicenter Study of Black and White Patients with mCRPC Treated with Abiraterone Acetate and Prednisone

Prospective Study of Apalutamide and Abiraterone Acetate iN ChemoTHerapy-Naïve mEn With mCRPC Stratified by Race


Biographies:
Daniel George, MD

Charles J. Ryan, MD